Cannabis Science, Inc. : Cannabis Science Issues Corporate & Operations Guidance to Shareholders in Regards to Dividend, Market Potential, and Anecdotal Reports
02/02/2012 | 02:40pm
Cannabis Science, Inc. (OTCBB:CBIS.ob
- News),
a pioneering US biotech company developing pharmaceutical cannabis
products, is pleased to report an overall corporate and operations
guidance outlook as very positive for 2012.
Cannabis Sciences' analysis of the worldwide market potential for its
formulations for medical cannabis treatments of critical ailments
include three main markets for distribution: FDA approved prescriptions,
OTC Non-psychoactive nutraceuticals, and licensed dispensaries in legal
Medical Marijuana states (currently 16).
Due to this successful self medicating patient use of our cannabis
extract based formulations in Colorado and other international anecdotal
cases reports from patients with Cancer, Cannabis Science is pursing its
FDA initiatives immediately with its initial indication targets
including basal cell and squamous cell carcinomas.
The Company is currently tracking several self medicating cancer
patients, there have been anecdotal reports, apparently successful, of
self-medicated cannabis treatment for several cancer patients, including
one whose physician said it was "the worst case of squamous cell
carcinoma cancer he had ever seen," while another physician refused to
continue tending. Images and biopsy reports available on the www.cannabisscience.com
website.
Cannabis Science is currently assessing market makers for the required
15c211 filing for the new class of shares to commence trading. The
15c211 filing is one of the many steps required to issue and commence
trading with the new class of shares to be issued from the dividend
including a new CUSIP number and new trading symbol.
On November 3, 2011, Cannabis Science, Inc.(the "Company"), filed an
amendment to its Articles of Incorporation to create an additional class
of common stock pursuant to the Company's Definitive Information
Statement on Schedule 14C which was filed with the Securities and
Exchange Commission on August 18, 2011 (information incorporated by
reference herein).
Upon completion, the Company will have three classes of shares: Class A
Common Stock (new class), Class B Common Stock (current class) and
Series A Preferred Stock. Only two of the classes will trade; Class A
Common and Class B common will each trade with its own separate trading
symbol. The Company will issue the dividend to its shareholders of
record as of December 31, 2010, so they receive 1 share of the new Class
A common stock and 1 non-transferable share purchase warrant for each 10
shares of the current common stock that they owned as of the shareholder
record date. The Company will continue to report progress as the process
continues to move forward until competition.
The company has announced that they have a variety of cannabis-based
formulations that target critical ailments worldwide as outlined in the
company website. Illnesses ranging from cancer to pain management give
the company a large market and revenue base potential. The Company has a
patient oriented, holistic approach to healing with whole plant cannabis
extract formulations. We are dedicated to working with Federal, State,
and Local regulatory agencies, as well as similar agencies in other
countries such as Health Canada, and other international regulatory
bodies.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade
medical marijuana research and development. The Company works with world
authorities on phytocannabinoid science targeting critical illnesses,
and adheres to scientific methodologies to develop, produce and
commercialize phytocannabinoid-based pharmaceutical products. In sum, we
are dedicated to the creation of cannabis-based medicines, both with and
without psychoactive properties, to treat disease and the symptoms of
disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Act of 1934. A statement containing works such as
"anticipate," "seek," intend," "believe," "plan," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated by
these forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on
existing regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does it
intend to update the results of these forward-looking statements.
Cannabis Science
Robert Kane, 561-234-6929
Investor
Relations
rkane@cannabisscience.com
or
Dr.
Robert Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
© Business Wire 2012
